Search results

Order by most recent / most popular / relevance

Results: 1-6 of 6

Health Canada announces intent to develop a framework for orphan drug approval

Torys LLP
-
Canada, USA
-
October 5 2012

On October 3, 2012, Health Canada issued a press release announcing that it will develop a framework for the marketing approval of drugs to treat rare life-threatening, seriously debilitating or serious chronic rare diseases that are commonly referred to as "orphan drugs."

Supreme Court of Canada rules on data protection for drug innovators

Torys LLP
-
Canada
-
February 8 2012

On February 3, 2012, the Supreme Court of Canada released its long-awaited decision in Merck Frosst Canada Ltd. v. Canada (Health), the culmination of over a decade of litigation between Merck and the Minister of Health

Court affirms Health Canada’s broad discretion in review of drug submissions

Torys LLP
-
Canada
-
April 13 2010

In a recent decision of the Federal Court in Hospira Healthcare Corporation v. Canada (Attorney General) the Court affirmed that Health Canada has broad discretion in interpreting the Food and Drug Regulations to determine the content of an application for the marketing approval of a drug

Oh, Canada patents in the true north: strong but not free

Torys LLP
-
Canada
-
April 9 2010

Canadians have oft been viewed internationally as friendly, agreeable and deferential - a strong, proud nation of peacekeepers

Abuse of process clarified by Canadian Federal Court of Appeal

Torys LLP
-
Canada
-
June 26 2009

In a recent decision, Apotex Inc. v. Janssen-Ortho Inc, the Federal Court of Appeal has limited the scope of the abuse of process doctrine in applications under the Patented Medicines (Notice of Compliance) Regulations

Canada’s Federal Court of Appeal limits damages available to delayed generics

Torys LLP
-
Canada
-
June 8 2009

On June 4, 2009, in Merck Frosst Canada Inc. v. Apotex, Inc., the Federal Court of Appeal released an important decision limiting the range of damages available in actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations

Search results

Health Canada announces intent to develop a framework for orphan drug approval

Supreme Court of Canada rules on data protection for drug innovators

Court affirms Health Canada’s broad discretion in review of drug submissions

Oh, Canada patents in the true north: strong but not free

Abuse of process clarified by Canadian Federal Court of Appeal

Canada’s Federal Court of Appeal limits damages available to delayed generics

Current Search

Suggested Facets

Author

Workarea